SNY - Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? | Benzinga
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) company, for the remaining interests in botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for X-linked retinitis pigmentosa (XLRP).
MeiraGTx will monetize potential future royalties and milestones related to bota-vec, with J&J acquiring the remaining rights for developing, manufacturing, and commercializing bota-vec.
MeiraGTx is to receive $130 million in upfront and near-term milestone payments, including $65 million at signing, an ...